81938-43-4 Usage
Antihypertensives
Zofenopril calcium is an angiotensin converting enzyme inhibitor (ACEI) class of anti-hypertensive drugs, it is successfully developed by the US Bristol-Myers Squibb Company for the first time. It is introduced to market by the Italian Menarini pharmaceutical ,on January 8, 2001, for the first time it is listed in Italy and other European countries, trade names Bifril, Zofenil, Zopranol, it is useful in the treatment of mild to moderate essential hypertension, as well as for acute myocardial infarction patients within 24 hours, symptomatic or asymptomatic, hemodynamically stable and not receiving thrombolytic therapy. This product can significantly reduce mortality of cardiovascular disease in high-risk patients and incidence of life-threatening cardiovascular events, ,which lays a sound basis for the prevention and treatment of cardiovascular disease, showing a bright future. These drugs are more attractive in treatment of patients with hypertension (they have a higher incidence of coronary heart disease risk than the normal blood pressure population ) .
Angiotensin-converting enzyme inhibitors (ACEI) is an important kind of anti-hypertensive drugs, since 1981, the first orally active angiotensin converting enzyme inhibitor (ACEI) captopril was listed, there has been at least 20 species of ACEI on the market, this year under the calcium channel blocker (CCB), a non-peptide angiotensin ⅱ (AngⅡ) receptor inhibitor leading the general trend of the market , ACEI kinds of drugs are still unique, occupying 1/5 of the world cardiovascular drug market share ,they ease the crisis of hundreds of millions of primary, secondary hypertension patients . In recent years a number of large-scale clinical studies have shown that ACEI has a protective effect on the heart, blood vessels and kidneys , especially for heart protection, clinical manifestations:
1. increase coronary blood flow.
2. reduce the left ventricular hypertrophy.
3. reduce the recurrence rate and mortality of myocardial infarction .
4. Mitigate pathological ventricular remodeling and dysfunction.
5. reduce the incidence and mortality of congestive heart failure.
Furthermore, ACEI also achieves gratifying results in the treatment of diabetic nephropathy .
Pharmacological effects
Zofenopril calcium is a long-acting ACE inhibitor containing a mercapto group on the chemical structure, it is a prodrug, having lipophilic character , in vivo it plays efficacy as free thiol group zofenopril by esterase hydrolysis. Because the role of thiol group, it has stronger antioxidant properties. In addition to having the general ACEI effect of the treatment of hypertension and congestive heart failure , it also combines a unique effect on myocardial infarction.
Zofenopril calcium compared to other ACE inhibitors, it has the following advantages:
1. zofenopril and captopril can protect the myocardium, and resist myocardial ischemia, high concentrations of enalapril, ramiprilat, Fosinoprilat have no myocardial protection.
2. strong lipophilic, high concentrations in the heart. zofenopril calcium is 200 times higher than Enalapril , and 1,500 times higher than ramipril in the heart.
3. it can be significant and long-term in cardiac ACE inhibition. Captopril and fosinopril also have this effect, but they have shorter duration of action.
4. it can improve left ventricular function after ischemia, increase coronary blood flow, reduce creatine kinase (CK) release, but fosinopril does not have this effect.
5. against the heart and other target organ damage caused by free radicals, the effect strength is better than others.
Zofenopril calcium ,in addition to similar anti-hypertension and congestive heart failure like other ACE inhibitors ,can prevent and treat myocardial infarction ,it may become the drug of choice for the treatment and prevention of myocardial infarction with hypertension .
The above information is edited by the lookchem of Tian Ye.
Uses
Different sources of media describe the Uses of 81938-43-4 differently. You can refer to the following data:
1. ACEI (angiotensin-converting enzyme inhibitors) class of antihypertensive drugs
2. Angiotensin-converting enzyme ACE inhibitor. A prodrug that is de-esterified to the active inhibitor, the sulfhydryl group containing metabolite, Zofenoprilat
3. adenosine A2a receptor agonist
Description
Different sources of media describe the Description of 81938-43-4 differently. You can refer to the following data:
1. Zofenopril is a prodrug form of the angiotensin-converting enzyme (ACE) inhibitor zofenoprilat. Zofenopril is hydrolyzed by cardiac esterases in vivo to form zofenoprilat. It inhibits ACE with an IC50 value of 0.9 nM in heart tissue homogenates and inhibits cardiac ACE activity in isolated perfused rat hearts. It reduces mean arterial blood pressure in two kidney-one clip renal hypertensive (2K-1C) rats and spontaneously hypertensive rats (SHRs) when administered at doses of 2.2, 6.6, and 22 mg/kg. Unlike the ACE inhibitor ramipril , zofenopril does not affect bronchoalveolar lavage fluid (BALF) levels of bradykinin or prostaglandin E2 (PGE2; ) or increase coughing induced by citric acid in guinea pigs.
2. Zofenopril calcium was introduced as a second-generation angiotensinconverting
enzyme (ACE) inhibitor for the treatment of acute myocardial infarction.
Zofenopril, rapidly hydrolyzed by cardiac esterase, is actually a S-benzoyl prodrug of the
active component zofenopril-sulfhydryl (zofenoprilat), the latter being the ACE inhibitor
responsible for the improvement of postischemic contractile function and for the reduction
of cardiac cell death. It was suggested that ACE inhibition alone was not sufficient to
explain the cardioprotective effects; the antioxidant properties demonstrated in vitro and in
viva could partly explain the strong anti-ischemic effects. In rats with CHF after myocardial
infarction, zofenopril attenuated ventricular enlargement and cardiac hypertrophy. It was
also shown in isolated globally ischemic rat hearts that the cardioprotective effect of
zofenopril was stereoselective. Clinical studies in healthy volunteers comparing zofenopril
with enalapril demonstrated that the rate of hydrolysis of the former was faster; at 30 or 60
mg, ACE was completely inhibited in most volunteers until 12h after administration. In
patients with anterior acute myocardial infarction, a g-week treatment with zofenopril
significantly reduced the incidence of death or severe CHF and also improved the chance
of surviving the next year.
Chemical Properties
Off-White to Light Yellow Crystalline Solid
Originator
Bristol-Myers Squibb (US)
Definition
ChEBI: An organic calcium salt that is the hemicalcium salt of zofenopril. A prodrug for zofenoprilat.
Brand name
Zoprace (Bristol-Myers Squibb);Zantipres.
Therapeutic Function
Antihypertensive
Check Digit Verification of cas no
The CAS Registry Mumber 81938-43-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,1,9,3 and 8 respectively; the second part has 2 digits, 4 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 81938-43:
(7*8)+(6*1)+(5*9)+(4*3)+(3*8)+(2*4)+(1*3)=154
154 % 10 = 4
So 81938-43-4 is a valid CAS Registry Number.
InChI:InChI=1/2C22H23NO4S2.Ca/c2*1-15(14-28-22(27)16-8-4-2-5-9-16)20(24)23-13-18(12-19(23)21(25)26)29-17-10-6-3-7-11-17;/h2*2-11,15,18-19H,12-14H2,1H3,(H,25,26);/q;;+2/p-2/t2*15-,18+,19+;/m11./s1
81938-43-4Relevant articles and documents
A PROCESS FOR THE PREPARATION OF ZOFENOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
-
Page/Page column 33-34, (2010/08/08)
The present invention relates to a process for the preparation of zofenopril and its pharmaceutically acceptable salts and a pharmaceutical composition thereof. The present invention also provides structurally novel compounds, which are useful intermediates in the synthesis of zofenopril.
NOVEL CRYSTALLINE FORMS
-
Page/Page column 15, (2009/10/21)
The present invention relates to two novel crystalline forms of zofenopril calcium, to processes for their preparation and their use in pharmaceutical compositions.
ZOFENOPRIL CALCIUM
-
Page/Page column 10, (2008/06/13)
The present invention relates to zofenopril calcium form (A) substantially free of other forms of zofenopril calcium and to zofenopril calcium having a chemical purity of more than 98.5%. The present invention also relates to methods of preparing such zofenopril calcium. It further relates to compositions comprising such zofenopril calcium. Zofenopril calcium, (4S)-l-[(2S)-3-benzoylthio-2-methylpropionyl]-4-(phenylthio)-L-proline calcium salt, has the following structure.